Press Release


Ascletis Successfully Listed on the Main Board of HKEX
Aug 01, 2018 21:02 JST
Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital market has been opened up further, welcoming listing applications from several biotechnology companies.
More info..

Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA
Aug 01, 2018 18:35 JST
Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China.
More info..

Ascletis-developed Ganovo Acquired Extraordinary Achievement
Jul 31, 2018 20:30 JST
Ascletis announced on July 30, 2018 that the Ganovo phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association.
More info..

Latest Release


More Latest Release >>